advertisement
Ward CL 9
Showing records 1 to 9 |
Display all abstracts from Ward CL69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyHarris A
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised studyMiller Ellis E; Berlin MS
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyWard CL; Rowe-Rendleman CL
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised studyWard CL
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyOuchi T
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised studySharpe JA
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyWood A
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised studyJamil A; Harris A
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyFujii A; Serle JB
Journal of Glaucoma 2016; 25: e826-e833
Issue 18-2
Change Issue
advertisement